{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-103528","form_type":"8-K","ticker":"UPB","cik":"0002022626","company_name":"Upstream Bio, Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.846634+00:00","generated_at":"2026-05-17T20:03:04.949213+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Upstream Bio Q2 net loss $40.0M; cash $393.6M; CRSwNP Phase 2 data on track for Q3 2025","bullets":["Net loss of $40.0M in Q2 2025 vs. $14.7M in Q2 2024; R&D expense rose to $37.9M from $14.1M.","Cash, equivalents and short-term investments $393.6M as of June 30, 2025; expected to fund operations through 2027.","Phase 2 CRSwNP (VIBRANT) top-line data expected Q3 2025; severe asthma (VALIANT) enrollment complete, top-line Q1 2026.","First patient dosed in Phase 2 COPD trial (VENTURE) in July 2025; LTE study for severe asthma initiated May 2025.","General and administrative expenses $7.4M in Q2 2025, up from $4.0M in Q2 2024, driven by personnel and professional fees."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-103528","json":"https://secwatch.observer/filing/0000950170-25-103528.json","markdown":"https://secwatch.observer/filing/0000950170-25-103528.md","text":"https://secwatch.observer/filing/0000950170-25-103528.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022626/000095017025103528/0000950170-25-103528-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022626/000095017025103528/upb-20250806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:03:04.949213+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}